Recently, though, the United States has been short of sodium thiopental. Hospira, the only domestic supplier, serving more than 3,400 medical facilities, stopped producing it in late 2009 because of problems obtaining its active ingredient from another company. For various business reasons, Hospira found that Italy was the best place to restart production.